MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

TransMedics Group Inc

Abierto

SectorSalud

91.01 -3.32

Resumen

Variación precio

24h

Actual

Mínimo

90.97

Máximo

95.02

Métricas clave

By Trading Economics

Ingresos

2.6M

6.9M

Ventas

13M

122M

P/B

Media del Sector

81.981

57.333

BPA

0.19

Margen de beneficio

5.638

Empleados

728

EBITDA

3.2M

16M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+8.4% upside

Dividendos

By Dow Jones

Próximas Ganancias

8 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

397M

3B

Apertura anterior

94.33

Cierre anterior

91.01

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

TransMedics Group Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

20 sept 2024, 03:29 UTC

Principales Noticias

Dow Jones Futures: Meta, Apple, Tesla Lead New Buys In Big Rally. Pay Attention To This Key Shift. -- IBD

Comparación entre iguales

Cambio de precio

TransMedics Group Inc Esperado

Precio Objetivo

By TipRanks

8.4% repunte

Estimación a 12 meses

Media 100 USD  8.4%

Máximo 125 USD

Mínimo 80 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para TransMedics Group Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

8 ratings

5

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

88.48 / N/ASoporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Very Strong Bullish Evidence

Largo Plazo

Weak Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.